I don't see one with regards to Lympro. My best guess is that AMBS goes it alone with ICON and as the test rolls out and proves to be invaluable to BPs doing clinical trials, there will be some or a few BP that will make an offer and possibly a bidding war for the diagnostic. Why do I say that? Because the company per comments from Gerald seem to want to extract as much money as they can get from Lympro.